Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00376415
Other study ID # R21AT001944
Secondary ID R21AT001944TICIP
Status Completed
Phase Phase 1
First received September 12, 2006
Last updated September 29, 2016
Start date September 2004
Est. completion date January 2005

Study information

Verified date September 2016
Source University of Missouri-Columbia
Contact n/a
Is FDA regulated No
Health authority South Africa: Medicines Control CouncilUnited States: Federal Government
Study type Interventional

Clinical Trial Summary

Lessertia frutescens (L.) Goldblatt & J.C. Manning (syn. Sutherlandia frutescens (L.) R. Br.), infusions and decoctions are widely used in South Africa as indigenous medicines, to combat cancer, infections and symptoms associated with AIDS. The aim of this study was to evaluate the safety of this phytotherapy in healthy adults.


Description:

Objectives: Lessertia frutescens (L.) Goldblatt & J.C. Manning (syn. Sutherlandia frutescens (L.) R. Br.), infusions and decoctions are widely used in South Africa as indigenous medicines, to combat cancer, infections and symptoms associated with AIDS. The aim of this study was to evaluate the safety of this phytotherapy in healthy adults.

Design: A randomised, double blind, placebo-controlled trial to evaluate the safety of Lessertia frutescens in healthy adults.

Setting: Karl Bremer Hospital, Bellville, South Africa.

Participants: 25 adults, aged 18 to 45 years, who provided informed consent. They had no significant diseases or clinically abnormal laboratory blood profiles during screening. They had no history of allergic conditions and were not on regular medical treatment.

Intervention: 12 healthy participants were randomized to a treatment arm where they received 400mg L. frutescens leaf powder capsules twice daily (800mg/day), available as a product called Sutherlandia. 13 healthy participants were randomized to the control arm, where they received an identical placebo capsule. The trial lasted 3 months.

Outcome Measures: The primary endpoint was frequency of adverse events and the secondary endpoint, changes in physical, vital, blood and biomarker indices.

Results: There were no significant differences in general adverse events, cardiovascular, CNS, GIT, infection, allergy, malaise, most physical, haematological, biochemical or physiological parameters, between the treatment and the placebo groups (P>0.05). However, subjects consuming L. frutescens mostly reported improved appetite compared to those in the placebo group (P<0.01). Although the treatment group exhibited a lower respiration rate (P<0.04), higher platelet count (P<0.03), MCH (P<0.01), MCHC (P<0.02), total protein (P<0.03) and albumin levels (P<0.03), than the placebo group, these differences remained within the normal physiological range, and were not clinically relevant. The L. frutescens biomarker, Canavanine, was undetectable in subject plasma.

Conclusion: Overall, consumption of 800mg/day L. frutescens leaf powder capsules, was well tolerated by healthy adults.


Other known NCT identifiers
  • NCT00200772

Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date January 2005
Est. primary completion date January 2005
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

Healthy males and females between 18 and 45 years of age will:

- be informed of the nature of the study and will give written informed consent;

- have body weights within 25% of the appropriate range;

- have no significant decreases or clinically abnormal laboratory values during screening;

- have 12 lead ECG without significant abnormalities;

- be on no regular medical treatment;

- be able to communicate effectively with study personnel.

Exclusion Criteria:

- Any disease or condition which might compromise the haematopoietic, renal, endocrine, pulmonary, central nervous system, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.

- History of allergic conditions - asthma, urticaria and eczema.

- History of autoimmune disorders - Lupus erythematosis.

- History or presence of dyspepsia, gastric ulcer or duodenal ulcer.

- History of psychiatric disorders.

- Intake of any medication within 14 days before the start of the study.

- Recent history of alcoholism (<2 years) or consumption of alcohol within 48 hours of receiving study medication.

- Smokers who smoke more than 10 cigarettes per day and cannot refrain from smoking during the study period.

- Presence of clinically significant abnormal laboratory results during screening.

- Pregnancy or not using appropriate means of contraception.

- Use of any recreational drugs or a history of drug addiction.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Lessertia Fructescens
Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
Placebo
Participants received an identical placebo capsule twice daily for 3 months.

Locations

Country Name City State
South Africa Tiger Trial Centre Tygerberg Western Cape

Sponsors (3)

Lead Sponsor Collaborator
University of Missouri-Columbia National Center for Complementary and Integrative Health (NCCIH), University of the Western Cape

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events Through end of study Yes
Secondary Change in study drug biomarker levels Biomarker, Canavanine, was measured Through end of study No
Secondary Change in appetite Through end of study No
Secondary Change in respiration rate Through end of study No
Secondary Change in complete blood count Through end of study No
Secondary Change in serum protein levels Through end of study No
Secondary Change in serum albumin levels Through end of study No
See also
  Status Clinical Trial Phase
Completed NCT01425502 - Data-driven Quality Improvement in Primary Care - Trial N/A
Recruiting NCT01756183 - Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer Phase 2
Completed NCT01355016 - A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers Phase 1
Completed NCT01757860 - Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects Phase 1
Completed NCT01179854 - Remegal Different Doses in Patients With Refractory Partial Seizures Phase 2
Active, not recruiting NCT01722916 - Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase Early Phase 1
Completed NCT01727778 - Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01475097 - Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography Phase 4
Completed NCT01412658 - Clinical Safety of a Novel Milk Protein Peptide Phase 1
Terminated NCT01847222 - An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATEā„¢ in Healthy Volunteers. Phase 1
Unknown status NCT01633099 - Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Phase 3
Recruiting NCT01297842 - Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections Phase 4
Completed NCT01284582 - Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) Phase 1
Completed NCT01557270 - Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery Phase 3
Completed NCT01556607 - A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma Phase 1
Completed NCT01319903 - Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 Phase 1
Completed NCT01271569 - A Study to Assess the Efficacy and Safety of Fospropofol Disodium Phase 1
Recruiting NCT04785027 - Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis Phase 1/Phase 2
Completed NCT01428882 - Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy Phase 4
Completed NCT01367873 - Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects Phase 1